Accelerate Data & Deal-Making Through China's Clinical Trial Ecosystem

We focus on quality of audience, not quantity and are aiming for a group of around 100 attendees for our inaugural Summit.  We believe that this is the right number to ensure that our audience is made up of mostly clinical development decision-makers from the pharmaceutical and biotech sectors from the US and China.

2026 Hot Topics

• How To Successfully File IND in US (Individually or Simultaneously with China)

• Key Considerations When Developing Your Strategy for Parallel Clinical Development for US and China

• Navigating the US FDA: What Chinese BioPharma Must Know

• Navigating China's Regulatory Agency (CFDA): What US BioPharma Must Know

Who You'll Meet

Biotechs

Both those evaluating China/Asia as a strategic advantage and those who have already executed accelerated programs.

Investors

Life science investors seeking portfolio companies with accelerated timelines and capital-efficient development, plus those conducting diligence on China-enabled programs and evaluating data quality for investment decisions. 

CROs

Execution partners with the operational scale and geographic breadth to deliver high-quality accelerated trials.

Conference Organizer You Can Trust

ChinaTrials+US is organized by Lychee Group, the same team that organizes ChinaTrials: Clinical Development Leaders' Summit in  Shanghai, Japan Medical Affairs Summit in Tokyo and China Medical Affairs Summit, some of which have been running successfully for over ten years now.  We also help organize most of the top global healthcare events in China that you’ve probably heard of including China Healthcare Investment Conference (CHIC), Healthcare Capital & Connections Summit (HCCS) and BioCentury's China Healthcare Summit.